In 2019, Ibn Al-Haytham led SEST, a post-marketing observational study evaluating the efficacy, safety, and tolerability of Sitacretin in managing patients with Type 2 diabetes not in theory, but in actual medical practice in Syria.
Study Scope

• Patients: 711
• Participating Doctors: 33
• Setting: Diverse outpatient environments across the country

Here’s what the real-world data revealed:
Efficacy Ratings:

• 52.18 % Excellent
• 27.71 % Good
• 7.88% Fair
• 2.39% Poor
   

Mean reduction in HbA1C from baseline, after 3 months: 13.62 % (from 8.70 to 7.51)
These outcomes reinforce Sitacretin’s role as a reliable option in real‑world diabetes management.

Safety & Tolerability Ratings

• 66.53% Excellent
• 15.19% Good
• 1.55% Fair
• 0.42% Poor

Most common side effect reported was GI discomfort 3.8%.

The reported side effects were mild 81%, 14% were moderate and no severe side effect.

Beyond Numbers...
This study didn’t just measure molecules—it measured lives impacted, trust earned, and clinical realities navigated.
Local evidence matters especially in regions where clinical realities differ from global averages.
And at Ibn Al‑Haytham, we believe credibility isn’t claimed—it’s demonstrated through transparent data, regional relevance, and patient‑first insights.